TCR2 Therapeutics Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -7.87 | -100% |
| P/S |
|
0 | 33.77 | -100% |
|
|
| P/BV |
|
0.2282 | 4.83 | -95.27% |
|
|
| P/FCF |
|
-0.6578 | 61 | -101.08% |
|
|
| Ev/Ebitda |
|
-0.5931 | -22.17 | -97.32% |
|
|
| Ev/S |
|
0 | 22.57 | -100% |
|
|
| Ev/FCF |
|
-0.4551 | 68.76 | -100.66% |
|
|
| E/P |
|
-1.97 | 0.0178 | -11183.8% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.97 | -100% | 0 | 0% |
| ROE |
|
-71.9 | 9.61 | -848.02% |
|
|
| ROA |
|
-57.12 | 0.3443 | -16691.6% |
|
|
| ROIC |
|
-30.91 | 7.63 | -504.88% |
|
|
| ROS |
|
0 | -25.17 | -100% |
|
|
| ROCE |
|
-106.47 | 15.45 | -789.13% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.6004 | -3.68 | -83.67% | -0.5348 | +12.28% |
| Nеt Debt/Ebitda |
|
-0.2344 | -3.44 | -93.18% |
|
|
| Debt/Ratio |
|
0.2584 | 0.1986 | 30.12% |
|
|
| Debt/Equity |
|
8.68 | 1.66 | 421.99% |
|
|
| Debt/Net Income |
|
-0.3544 | 10.32 | -103.43% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.541 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2256 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9598 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4928 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.541 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | -57.64 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
122.49 | -90.94 | -234.69% | ||
| Growth impulse Net Income in 5 years |
|
148.13 | -97.8 | -251.46% | ||
| Growth impulse FCF in 5 years |
|
175.49 | -108.72 | -261.41% | ||
| Growth impulse EPS in 5 years |
|
-39.29 | -142.05 | -72.34% |
IP Score
3.55/10
